Company
Adelaide, SA
Every investor coverage indicates participated in a round Royal Adelaide Hospital raised.
Companies Royal Adelaide Hospital acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
| Name | Role | Sources |
|---|---|---|
| Professor Chris Rayner | Gastroenterologist | Brandon Capital portfolio, Brandon BioCatalyst portfolio |
| Professor Christopher Rayner | Consultant Gastroenterologist | Brandon BioCatalyst portfolio |
| Professor Prash Sanders | Clinician-Scientist (former) | Brandon BioCatalyst, Brandon Capital |
Stories naming Royal Adelaide Hospital. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Adelaide medtech Ferronova has banked another $6 million from returning backers to advance its surgical tracer for cancer, lifting Series A funding to $17.5 million; backer parent UltraGreen.ai floated in Singapore this month.
Also movefm.com.au
Adelaide biotech Ferronova added $6 million to its Series A from prior backers, lifting the round's total to $17.5 million; backer Renew's parent Ultragreen.ai floated in Singapore this month.
Also ferronova.com.au·movefm.com.au·Biotech Dispatch·Startup Daily
Micro-X will trial its lightweight portable CT brain scanner at two hospitals this year; the Adelaide company's stroke technology was developed with $8 million in grant funding, as was rival EMVision's approach.
Cardiac pacing company EBR Systems says its SOLVE-CRT trial hit its safety and efficacy goals early, keeping a 2024 US approval bid on course; the article also recalls its 2021 ASX listing.
Adelaide biotech Ferronova raised $11 million for its cancer-detection nanotechnology, with Renew Pharmaceuticals and a government CRC contributing, following an earlier $4.6 million Series A in 2020.
Also SmartCompany
Adelaide cancer-focused biotech Ferronova has secured fresh backing: an investor round led by Irish strategic partner Renew Pharmaceuticals plus a federal research grant, to speed clinical trials in stomach and brain cancers.
Also SmartCompany·SmartCompany·SmartCompany·Startup Daily·Business News Australia·Startup Daily
Adelaide biotech Ferronova announced an A$11 million package: an A$8 million round led by Ireland's Renew Pharmaceuticals plus an A$3 million government CRC-P grant, with existing shareholders Uniseed and Artesian also participating.
Glyscend reports encouraging Phase 1 biomarker data for its diabetes drug GLY-200, announces US FDA clearance of its investigational new drug application, and has begun enrolling patients in a Phase 2 trial.
Glyscend Therapeutics, a Johns Hopkins spin-out, is starting a Phase I trial of its type 2 diabetes pill in Adelaide; the piece recalls its AUD$29 million Series A led by Brandon Capital's MRCF.
Also Brandon BioCatalyst portfolio·Brandon BioCatalyst portfolio
Adelaide-backed biotech Glyscend is recruiting volunteers for phase 1 trials of a pill mimicking gastric bypass surgery to treat type 2 diabetes, funded with $29 million from Brandon Capital's MRCF, Santé Ventures and Breakout Labs.
Also Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio
Glyscend Therapeutics, an Adelaide-Baltimore biotech, is recruiting volunteers for phase 1 trials of GLY-200, a pill mimicking gastric bypass for type 2 diabetes, developed with $29 million from MRCF, Santé Ventures and Breakout Labs.
Also Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon Capital portfolio·Brandon Capital portfolio
Glyscend's diabetes pill has raised $29 million with backing from Brandon Capital, Santé Ventures and Breakout Labs, ahead of planned human trials in Adelaide.
Also Brandon Capital portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon Capital portfolio
Okogen has begun Australian Phase II trials of its conjunctivitis therapy OKG-0301 across multiple sites, with Brandon Capital's MRCF having invested in the biotech's Series A in December 2017.